AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (withdrawn): A method of inhibiting~~An inhibitor of~~ IL-6 production comprising administering to a subject in need of treatment an effective amount of, a hydroxamic acid derivative of the formula (I):



(I)

wherein, R^1 is

(a) C1-8 alkyl,

(b) C2-8 alkenyl,

(c) C2-8 alkynyl,

~~(d) halogen,~~

~~(e) nitro,~~

~~(f) nitrile,~~

~~(g) trifluoromethyl,~~

~~(h) trifluoromethoxy,~~

~~(i) OR^2,~~

~~(j) SR^2,~~

~~(k) $-NR^3R^4$;~~

~~(l) $-COR^5$;~~

~~(m) keto;~~

~~(n) Cyc1;~~

(o) C1-8 alkyl substituted by $-OR^2$, $-SR^2$, $-NR^3R^4$, $-COR^5$ or Cyc1,

~~(p) $-SO_2R^{10}$;~~

~~(q) –O–(C1-8 alkylene)–OR^{11};~~

~~(r) C1-8 alkyl substituted by nitrile, $-SO_2R^{10}$ or –O–(C1-8 alkylene)–OR^{11};~~

~~(s) –O–(C1-8 alkylene)–$NR^{12}R^{13}$;~~

~~(t) –S–(C1-8 alkylene)–$NR^{12}R^{13}$;~~

(u) C1-8 alkyl substituted by –O–(C1-8 alkylene)–$NR^{12}R^{13}$– or –S–(C1-8 alkylene)–$NR^{12}R^{13}$,

(v) C2-8 alkenyl substituted by $-OR^2$, $-SR^2$, $-NR^3R^4$, $-COR^5$, Cyc1, nitrile, $-SO_2R^{10}$, –O–(C1-8 alkylene)–OR^{11}, –O–(C1-8 alkylene)–$NR^{12}R^{13}$ or –S–(C1-8 alkylene)–$NR^{12}R^{13}$ or

(w) C2-8 alkynyl substituted by $-OR^2$, $-SR^2$, $-NR^3R^4$, $-COR^5$, Cyc1, nitrile, $-SO_2R^{10}$, –O–(C1-8 alkylene)–OR^{11}, –O–(C1-8 alkylene)–$NR^{12}R^{13}$ or –S–(C1-8 alkylene)–$NR^{12}R^{13}$,

R^2 is hydrogen, C1-8alkyl, C2-9 acyl or Cyc1,

R^3 and R^4 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

R^5 is hydroxy, C1-8 alkyl, C1-8 alkoxy, $-NR^6R^7$ or Cyc1,

R^6 and R^7 are each independently hydrogen, C1-8 alkyl or Cyc1,

R^{10} is C1-8 alkyl or Cyc1,

Cyc1 is morpholine, piperidine or piperazine~~C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom,~~;

R^{11} is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1~~,~~;

R^{12} and R^{13} are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

m is ~~0 or~~ an integer of 1-5~~,~~;

ring A is a benzene ring~~C3-15 mono-, bi- or tri-carbocyclic ring or 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s)~~;

ring B is a benzene ring~~C5-15 mono-, bi- or tri-carbocyclic aryl or 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s)~~;

E is a bond, –CH=CH– or –C≡C–;

R^8 is

(a) C1-8 alkyl,

(b) C1-8 alkoxy,

(c) halogen,

(d) nitro,

(e) nitrile,

(f) trifluoromethyl or

(g) trifluoromethoxy,

with the proviso that when E is a bond, then, optionally, R^1 and R^8, taken together, may be ~~optionally~~ C1-4 alkylene;

n is 0 or an integer of 1-5;

R^9 is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl;

a nontoxic salt thereof or a prodrug thereof, as an active ingredient.

2. (withdrawn): The method~~inhibitor of IL-6 production~~ described in claim 1, wherein the prodrug of a compound of the formula (I) as an active ingredient is represented by a compound of the formula (IA):



(IA)

~~(~~wherein, R^{14} is C1-8 alkyl substituted with C1-8 alkyl, C1-8 alkoxy, the other symbols have the same meanings as defined in claim 1.~~)~~.

3. (withdrawn): The method~~inhibitor of IL-6 production~~ described in claim 1, wherein the prodrug of a compound of the formula (I) as an active ingredient is represented by comprising a compound of the formula (IB):



(IB)

~~(~~wherein, the all symbols have the same meanings as defined in claim 1.~~)~~.

4. (currently amended): A hydroxamic acid derivative of the formula (I):



(I)

wherein, R^1 is

(a) C1-8 alkyl,

(b) C2-8 alkenyl,

(c) C2-8 alkynyl,

~~(d) halogen,~~

~~(e) nitro,~~

~~(f) nitrile,~~

~~(g) trifluoromethyl,~~

~~(h) trifluoromethoxy,~~

~~(i) OR^2,~~

~~(j) SR^2,~~

~~(k) NR^3R^4,~~

~~(l) COR^5,~~

~~(m) keto,~~

~~(n) Cyc1,~~

(o) C1-8 alkyl substituted by $-OR^2$, $-SR^2$, $-NR^3R^4$, $-COR^5$ or Cyc1,

~~(p) SO_2R^{10},~~

~~(q) –O–(C1-8 alkylene)–OR^{11};~~

~~(r) C1-8 alkyl substituted by nitrile, $–SO_2R^{10}$ or –O–(C1-8 alkylene)–OR^{11};~~

~~(s) –O–(C1-8 alkylene)–$NR^{12}R^{13}$;~~

~~(t) –S–(C1-8 alkylene)–$NR^{12}R^{13}$;~~

(u) C1-8 alkyl substituted by –O–(C1-8 alkylene)–$NR^{12}R^{13}$– or –S–(C1-8 alkylene)–$NR^{12}R^{13}$,

(v) C2-8 alkenyl substituted by $–OR^2$, $–SR^2$, $–NR^3R^4$, $–COR^5$, Cyc1, nitrile, $–SO_2R^{10}$, –O–(C1-8 alkylene)–OR^{11}, –O–(C1-8 alkylene)–$NR^{12}R^{13}$ or –S–(C1-8 alkylene)–$NR^{12}R^{13}$ or

(w) C2-8 alkynyl substituted by $–OR^2$, $–SR^2$, $–NR^3R^4$, $–COR^5$, Cyc1, nitrile, $–SO_2R^{10}$, –O–(C1-8 alkylene)–OR^{11}, –O–(C1-8 alkylene)–$NR^{12}R^{13}$ or –S–(C1-8 alkylene)–$NR^{12}R^{13}$,

R^2 is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

R^3 and R^4 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

R^5 is hydroxyl, C1-8 alkyl, C1-8 alkoxy, $–NR^6R^7$ or Cyc1,

R^6 and R^7 are each independently hydrogen, C1-8 alkyl or Cyc1,

R^{10} is C1-8 alkyl or Cyc1~~;~~;

Cyc1 is morpholine, piperidine or piperazine~~C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom;~~;

R^{11} is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1~~;~~;

R^{12} and R^{13} are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;

m is ~~0 or~~ an integer of 1-5;

ring A is a benzene ring~~C3-15 mono-, bi- or tri-carbocyclic ring or 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s)~~;

ring B is a bezene ring~~C5-15 mono-, bi- or tri-carbocyclic aryl or 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s)~~;

E is a bond, –CH=CH– or –C≡C–;

R^8 is

(a) C1-8 alkyl,

(b) C1-8 alkoxy,

(c) halogen,

(d) nitro,

(e) nitrile,

(f) trifluoromethyl or

(g) trifluoromethoxy,

with the proviso that when E is a bond then, optionally, R^1 and R^8, taken together, is C1-4 alkylene ~~optionally~~;

n is 0 or an integer of 1-5;

R^9 is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl~~,~~;

~~with the proviso that when E is -CH=CH- or -C≡C- , ring A is C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom,~~

a nontoxic salt thereof or a prodrug thereof.

5. (currently amended): The prodrug of a compound of the formula (I) described in claim 4, which is represented by the formula (IA):



(wherein, R^{14} is C1-8 alkyl substituted with C1-8 alkyl, C1-8 alkoxy, the other symbols have the same meaning as defined in claim [[1.)]] 4.

6. (currently amended): The prodrug of a compound of the formula (I) described in claim 4, which is represented by the formula (IB):



(wherein, the all symbols have the same meaning as defined in claim [[1.)]] 4.

7. (currently amended): The compound described in claim 4, wherein E is a bond ~~and ring A is C3-15 mono-, bi- or tri-carbocyclic ring~~.

8. (canceled)

9. (currently amended): The compound described in claim 4, wherein E is –CH=CH– or –C≡C– ~~and ring A is C3-7 mono-carbocyclic ring~~.

10. (canceled)

11. (currently amended): The compound described in claim 4, which is

~~(1) N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(2) N-hydroxy-6-(4-biphenyl)-6-hydroxyhexanamide,~~

~~(3) N-hydroxy-6-(4-cyclohexylphenyl)-6-hydroxyhexanamide,~~

~~(4) N-hydroxy-6-(4-(4-methylphenyl)phenyl)-6-hydroxyhexanamide,~~

~~(5) N-hydroxy-6-(4-(4-methoxyphenyl)phenyl)-6-hydroxyhexanamide,~~

~~(6) N-hydroxy-6-(4-(trans-4-propylcyclohexyl)phenyl)-6-hydroxyhexanamide,~~

~~(7) (R)-N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(8) (S)-N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(9) N-hydroxy-6-(4-(benzofuran-2-yl)phenyl)-6-hydroxyhexanamide,~~

~~(10) N-hydroxy-6-(4-(pyridin-4-yl)phenyl)-6-hydroxyhexanamide,~~

~~(11) N-hydroxy-6-(4-(pyridin-3-yl)phenyl)-6-hydroxyhexanamide,~~

~~(12) N-hydroxy-6-(4-(2-chlorophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(13) N-hydroxy-6-(4-(3-chlorophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(14) N-hydroxy-6-(4-(4-bromophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(15) N-hydroxy-6-(4-(thiophen-2-yl)phenyl)-6-hydroxyhexanamide,~~

~~(16) N-hydroxy-6-(4-(furan-2-yl)phenyl)-6-hydroxyhexanamide,~~

~~(17) N-hydroxy-6-(4-(1,3-dioxy-2,3-dihydroinden-5-yl)phenyl)-6-hydroxyhexanamide,~~

~~(18) N-hydroxy-6-(4-(4-methylthiophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(19) N-hydroxy-6-(4-(naphthalen-1-yl)phenyl)-6-hydroxyhexanamide,~~

~~(20) N-hydroxy-6-(4-(naphthalen-2-yl)phenyl)-6-hydroxyhexanamide,~~

~~(21) N-hydroxy-6-(4-(4-acetylphenyl)phenyl)-6-hydroxyhexanamide,~~

~~(22) N-hydroxy-6-(4-(4-hydroxyphenyl)phenyl)-6-hydroxyhexanamide,~~

~~(23) N-hydroxy-6-(4-(dibenzofuran-4-yl)phenyl)-6-hydroxyhexanamide,~~

~~(24) N-hydroxy-6-(4-(2-methoxyphenyl)phenyl)-6-hydroxyhexanamide,~~

~~(25) N-hydroxy-6-(4-(3-methoxyphenyl)phenyl)-6-hydroxyhexanamide,~~

~~(26) N-hydroxy-6-(4-(4-trifluoromethylphenyl)phenyl)-6-hydroxyhexanamide,~~

~~(27) N-hydroxy-6-(4-(4-t-butylphenyl)phenyl)-6-hydroxyhexanamide,~~

~~(28) (R)-N-hydroxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(29) (R)-N-hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(30) (R)-N-hydroxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide,~~

~~(31) (R)-N-hydroxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide,~~

~~(32) (R)-N-hydroxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(33) N-hydroxy-6-(4-(trans-4-butylcyclohexyl)phenyl)-6-hydroxyhexanamide,~~

~~(34) N-hydroxy-6-(4-(trans-4-hydroxycyclohexyl)phenyl)-6-hydroxyhexanamide,~~

~~(35) N-hydroxy-6-(4-cyclopentylphenyl)-6-hydroxyhexanamide,~~

~~(36) N-hydroxy-6-[4-(morpholin-4-yl)phenyl]-6-hydroxyhexanamide,~~

~~(37) N-hydroxy-6-[3-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide,~~

~~(38) N-hydroxy-6-[2-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide,~~

~~(39) N-hydroxy-6-[4-((1E)-2-phenylvinyl)phenyl]-6-hydroxyhexanamide,~~

~~(40) N-hydroxy-6-[4-((1E)-2-(pyridin-4-yl)vinyl)phenyl]-6-hydroxyhexanamide,~~

~~(41) N-hydroxy-6-[4-((1E)-2-(pyridin-2-yl)vinyl)phenyl]-6-hydroxyhexanamide,~~

~~(42) N-hydroxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxyheptanamide,~~

~~(43) N-hydroxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxy-7-octenamide,~~

~~(44) N-hydroxy-6-(4-biphenyl)-6-hydroxyheptanamide,~~

~~(45) (+) N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyheptanamide,~~

~~(46) (-) N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyheptanamide,~~

~~(47) (R) N-hydroxy-6-(4-biphenyl)-6-hydroxyhexanamide,~~

~~(48) (R) N-hydroxy-6-[4-(4-methylphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(49) (R) N-hydroxy-6-[4-(3-methylphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(50) (R) N-hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(51) (R) N-hydroxy-6-[4-(2-phenylethynyl)phenyl]-6-hydroxyhexanamide,~~

~~(52) (R) N-hydroxy-6-[4-(benzothiophen-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(53) (R) N-hydroxy-6-[4-(4-(cyanomethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(54) (R) N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(55) (R) N-hydroxy-6-[4-(4-propylphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(56) (R) N-hydroxy-6-[4-(4-biphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(57) (R) N-hydroxy-6-[4-(1-methylpiperidin-4-yl)phenyl]-6-hydroxyhexanamide,~~

~~(58) (R) N-hydroxy-6-[4-(indol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(59) (R) N-hydroxy-6-[4-(4-cyanophenyl)phenyl]-6-hydroxyhexanamide,~~

~~(60) (R) N-hydroxy-6-[4-phenyl-2-methylphenyl]-6-hydroxyhexanamide,~~

~~(61) (R) N-hydroxy-6-(4-cycloheptylphenyl)-6-hydroxyhexanamide,~~

~~(62) (R) N-hydroxy-6-(9,10-dihydrophenanthren-2-yl)-6-hydroxyhexanamide,~~

~~(63) (R) N-hydroxy-6-[4-(1-ethoxycarbonylpiperidin-4-yl)phenyl]-6-hydroxyhexanamide,~~

~~(64) (R) N-hydroxy-6-[4-(4-(N-methylcarbamoyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(65) (R) N-hydroxy-6-(4-cyclohexylphenyl)-6-hydroxyhexanamide,~~

~~(66) (R) N-hydroxy-6-[4-(5-hydroxybenzofuran-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(67) (R) N-hydroxy-6-[4-(2-(4-methylphenyl)ethynyl)phenyl]-6-hydroxyhexanamide,~~

~~(68) (R) N-hydroxy-6-[4-((1E)-2-(4-methylphenyl)vinyl)phenyl]-6-hydroxyhexanamide,~~

~~(69) (R) N-hydroxy-6-[4-(4-trifluoromethoxyphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(70) (R) N-hydroxy-6-[4-(4-ethylthiophenyl)phenyl]-6-hydroxyhexanamide,~~

~~(71) (R) N-hydroxy-6-[4-(4-methoxyphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(72) (R) N-hydroxy-6-[4-(4-(1-methylethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(73) (R) N-hydroxy-6-[4-(4-(N,N-dimethylcarbamoylmethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(74) (R) N-hydroxy-6-[4-(benzothiazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(75) (R) N-hydroxy-6-[4-(4-(methoxymethoxymethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(76) (R) N-hydroxy-6-[4-(6-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(77) (R) N-hydroxy-6-[4-(6-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(78) (R) N-hydroxy-6-[4-(4-methoxymethylphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(79) (R) N-hydroxy-6-[4-(5-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(80) (R) N-hydroxy-6-[4-(4-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(81)~~(1) (R)-N-hydroxy-6-[4-(4-(piperidin-1-ylmethyl)phenyl)phenyl]-6-hydroxyhexanamide,

~~(82) (R) N-hydroxy-6-[4-(4-hydroxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(83) (R) N-hydroxy-6-[4-(6-hydroxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(84) (R) N-hydroxy-6-[4-((1E)-2-(4-methylthiophenyl)vinyl)phenyl]-6-hydroxyhexanamide,~~

~~(85) (R) N-hydroxy-6-[4-(5-methoxybenzofuran-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(86) (R) N-hydroxy-6-[4-(5-methylthiobenzofuran-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(87) (R) N-hydroxy-6-[4-(4-(2-(dimethylamino)ethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(88) (R) N-hydroxy-6-[4-(4-(2-(dimethylamino)ethoxy)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(89) (R) N-hydroxy-6-[4-(4-(2-(diethylamino)ethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(90) (R) N-hydroxy-6-[4-(4-(2-hydroxyethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(91) (S) N-hydroxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide,~~

~~(92) (S) N-hydroxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide,~~

~~(93) (S) N-hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(94) (S) N-hydroxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(95) (S) N-hydroxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(96)~~(2) (R)-N-hydroxy-6-[4-(4-(morpholin-4-ylmethyl)phenyl)phenyl]-6-hydroxyhexanamide,

~~(97) (R) N-hydroxy-6-[4-(4-(dipropylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(98) (R) N-hydroxy-6-(5-phenylthiophen-2-yl)-6-hydroxyhexanamide,~~

~~(99) (R) N-hydroxy-6-(5-phenylbenzofuran-2-yl)-6-hydroxyhexanamide,~~

~~(100) (R) N-hydroxy-6-[4-(4-(methoxycarbonyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(101) (R) N-hydroxy-6-[4-(4-carboxyphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(102) (R) N-hydroxy-6-[4-(4-methylsulfonylphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(103) (R) N-hydroxy-6-[4-(4-hydroxymethylphenyl)phenyl]-6-hydroxyhexanamide,~~

~~(104)~~(3) (R)-N-hydroxy-6-[4-(4-(2-(morpholin-4-yl)ethoxy)phenyl)phenyl]-6-hydroxyhexanamide,

~~(105)~~(4) (R)-N-hydroxy-6-[4-(4-(2-(morpholin-4-yl)ethyl)phenyl)phenyl]-6-hydroxyhexanamide

or a nontoxic salt thereof.

12. (currently amended) The compound described in claim 5, which is:

~~(1) N-(1-methoxy-1-methyl)ethoxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,~~

~~(2) N-(1-methoxy-1-methyl)ethoxy-6-(4-(benzofuran-2-yl)phenyl)-6-hydroxyhexanamide,~~

~~(3) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(4) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,~~

~~(5) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide,~~

~~(6) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide,~~

~~(7) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(8)~~(1) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(morpholin-4-ylmethyl)phenyl)phenyl]-6-hydroxyhexanamide,

~~(9) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(dipropylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,~~

~~(10) N-methoxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide,~~

~~(11)~~(2) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(2-(morpholin-4-yl)ethoxy)phenyl)phenyl]-6-hydroxyhexanamide,

~~(12)~~(3) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(2-(morpholin-4-yl)ethyl)phenyl)phenyl]-6-hydroxyhexanamide,

or a nontoxic salt thereof.

13. (Canceled)